Trevi Therapeutics Q4 2023 GAAP EPS $(0.08) Beats $(0.09) Estimate
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics reported Q4 2023 GAAP EPS of $(0.08), surpassing the analyst consensus estimate of $(0.09) by 11.11%.
March 20, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trevi Therapeutics reported a smaller-than-expected quarterly loss, beating analyst estimates.
Beating earnings estimates typically leads to positive investor sentiment and can result in a short-term increase in stock price. The better-than-expected loss per share indicates operational efficiency or higher revenue than anticipated, which are positive signals for investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100